Mark, a ten-year veteran of the pharmaceutical R&D world with a Ph.D. in statistics, was the obvious choice to lead the SAS software and data management group of a global healthcare corporation when the current director suddenly departed. Having managed a small team of bio-statisticians successfully over three years, promoting him to director seemed like a no-brainer. Yet, within six months, despite being viewed as “high potential” by the C-suite, he had managed to alienate just about everyone.